Mutual fund · AMFI 135810
Tata India Pharma & HealthCare Fund
NAV ₹39.60 · 18 Nov 2026
Tata India Pharma & HealthCare Fund is a sectoral-pharma mutual fund run by Tata. Its NAV was ₹39.60 on 18 Nov 2026, up 10.4% over one year and 18.1% a year over three years. The direct plan's total expense ratio was 1.09% in the latest AMFI data. The top 10 holdings made up 50.1% of the portfolio in October 2026.
Returns from NAV
One year and shorter are absolute; three and five years are annualised. Based on NAV, so dividend payouts are not added back. Past performance does not guarantee future results.
Risk · last 3.0 years
How bumpy the ride has been
Worked out from weekly NAVs. The largest fall ran from 02 Jan 2025 to 28 Feb 2025. Sharpe and Sortino use a fixed 6.5% a year risk-free rate for comparison. Past figures are not a guide to future returns.
What the fund charges
From AMFI's expense ratio data, updated 19 Nov 2026. The regular plan charges more; see the fund's factsheet.
Portfolio · October 2026
Top holdings (39 in total)
| Company | % of fund | vs last month |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | -0.1 | |
| ABBOTT INDIA LTD | -0.28 | |
| DIVI LABORATORIES LTD | -0.27 | |
| HEALTHCARE GLOBAL ENTERPRISES LTD | -0.67 | |
| DR REDDYS LABORATORIES LTD | +0.49 | |
| TORRENT PHARMACEUTICALS LTD | +0.97 | |
| APOLLO HOSPITALS ENTERPRISE LTD | +0.19 | |
| MAX HEALTHCARE INSTITUTE LTD | +0.57 | |
| RAINBOW CHILDRENS MEDICARE LTD | -0.28 | |
| SAI LIFE SCIENCES LTD | +0.62 | |
| SYNGENE INTERNATIONAL LTD | +0.32 | |
| PROCTER & GAMBLE HEALTH LTD | +0.4 | |
| LUPIN LTD | -0.01 | |
| CIPLA LTD | -1.14 | |
| ANTHEM BIOSCIENCES LTD | +0.42 |
The top 10 make up 50.1% of the fund. Source: the fund house's monthly portfolio disclosure.
Since September 2026
What changed
New holdings
- NESTLE INDIA LTD1.09%
Exited
- FORTIS HEALTHCARE LTDwas 1.95%
- IPCA LABORATORIES LTDwas 0.91%
- MANKIND PHARMA LTDwas 0.77%
Biggest changes in weight
- PI INDUSTRIES LTD2.59% to 0.46%
- DR. LAL PATH LABS LTD1.76% to 0.03%
- BIOCON LTD0.69% to 2.23%
- SANOFI CONSUMER HEALTHCARE INDIA LTD0.57% to 1.99%
- NATCO PHARMA LTD1.51% to 2.86%
- CIPLA LTD4.22% to 3.08%
By sector
Where the money is
Pharmaceuticals & Biotechnology63.7%
Healthcare Services25.5%
Fertilizers & Agrochemicals4.2%
Chemicals & Petrochemicals3.5%
Personal Products1.2%
Food Products1.1%
Equity: Sectoral-Pharma
Other funds in this category
Six large funds in the same category, listed for comparison only.
Learn more
Mutual fund guides
Your mutual funds
Review your own mutual fund portfolio
Upload or fetch your holdings and see each fund's returns, cost and overlap against benchmarks, as facts. Review my mutual funds
Questions
About Tata India Pharma & HealthCare Fund
What is the NAV of Tata India Pharma & HealthCare Fund?
The net asset value was Rs 39.60 on 18 November 2026.
What is the expense ratio of Tata India Pharma & HealthCare Fund?
The direct plan's total expense ratio was 1.09% in the latest AMFI data, about Rs 10,900 a year on Rs 10 lakh invested.
What is the one-year return of Tata India Pharma & HealthCare Fund?
The NAV changed by 10.4% over the last year; past returns do not indicate future returns.
Data source: AMFI (Association of Mutual Funds in India) for NAVs and expense ratios; portfolio holdings from the fund house's monthly disclosures.
Data: AMFI NAVs and expense ratios and the fund house's monthly portfolio disclosures. This page states facts and is not a recommendation to buy or sell. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not guarantee future results.